Drug Discovery & Pharmaceuticals

RSS

Two compounds sourced from cannabis show promising anti-cancer effects

In the future, scientists could use drugs made from cannabis to fight ovarian cancer. A team of scientists testing the effects of two chemical compounds sourced from cannabis on ovarian cancer cells have found that both show promising anti-cancer effects.

15 Dec 2025

SN101 iPSC-derived therapy relieves chronic pain and preserves joints

SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on a novel approach to chronic pain management and joint tissue preservation.

12 Dec 2025

Novel nanomedicine mPEG@ELA-11 shows potential in treating atherosclerosis

A pioneering study led by researchers from Tongji University School of Medicine, Shanghai Jiao Tong University School of Medicine and Naval Medical University has unveiled a novel nanomedicine, mPEG@ELA-11, which demonstrates significant potential in treating atherosclerosis (AS), a leading cause of cardiovascular diseases globally.

12 Dec 2025

Exclusive licensing agreement accelerates PHD inhibitor development for anemia in CKD patients

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and TaiGen Biotechnology, a listed discovery-based and market-focused pharmaceutical company, as well as TaiGen Biopharmaceuticals, its wholly-owned Beijing subsidiary (both referred to as "TaiGen"), today announced an exclusive pipeline out-licensing collaboration.

12 Dec 2025

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint blockades in solid cancers.

12 Dec 2025

Collaborative project seeks safer therapies for ischemia and reperfusion injury

Southwest Research Institute (SwRI) and Trinity University will improve a prodrug, a compound activated in the body, to mitigate tissue and organ damage associated with heart attacks, strokes and traumatic injuries.

10 Dec 2025

Older chemical libraries yield new leads for next-generation COVID-19 antivirals

SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid.

8 Dec 2025

Ripple & Bausch’s licensing agreement: What it means in ocular delivery

Ripple Therapeutics, a clinical-stage company developing polymer-free sustained release drug delivery systems, has entered into an evaluation and licensing option agreement with an affiliate of Bausch + Lomb.

From Hanson Wade Group - 4th Ophthalmic Drug Delivery Summit 5 Dec 2025

Atelerix and Labskin partner to enable long-distance transport of advanced in vitro skin models

Atelerix, a biotech company revolutionizing cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced an agreement with Labskin, a global leader in laboratory-grown human skin models used for research, testing and product development.

2 Dec 2025

Generative AI aids discovery of ISM3830's novel scaffold

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and master negative regulator of T‑cell and natural killer (NK) cell activation, playing a central role in modulating T-cell activation and immune tolerance, and its inhibition enhances T cells and NK cells function, also provides a strategy for the function restoration of exhausted T cells.

1 Dec 2025

Designing better RNA delivery polymers with computational tools

A research team led by professor Olivia Merkel, Chair of Drug Delivery at LMU and co-spokesperson of the Cluster for Nucleic Acid Therapeutics Munich (CNATM) has developed the first integrated platform that combines molecular dynamics (MD) simulations and machine learning (ML) to identify new polymeric materials for therapeutic RNA delivery.

1 Dec 2025

Eli Lilly’s Adverum move: The future of ocular gene therapy at the 4th Ophthalmic Drug Delivery Summit

The race to develop safer, longer lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery.

From Hanson Wade Group - 4th Ophthalmic Drug Delivery Summit 26 Nov 2025

Freezing cells for success: DMSO-free redefining the future of cryopreservation

Cryopreservation plays a crucial role in cell biology research, bioprocessing, and biomanufacturing. Traditionally, DMSO (dimethyl sulfoxide) has been the cryoprotectant of choice for preserving cells.

From NIPPON Genetics EUROPE GmbH 25 Nov 2025

Research explores new solvent strategies to extend shelf life of injectable therapeutics

Sugar-based liquid solvents store crucial injection-based therapeutics such as insulin and vaccines.

22 Nov 2025

Promising long-term vaccine for Crimean-Congo hemorrhagic fever developed

Crimean-Congo hemorrhagic fever (CCHF) is one of the world's most dangerous yet overlooked infectious diseases.

22 Nov 2025

New light-activated method revolutionizes creation of drug building blocks

A team of organic and computational chemists at the University of Minnesota Twin Cities have created a new, modern tool to make the process of creating pharmaceuticals and agrochemicals faster, cost-effective, and energy-efficient.

21 Nov 2025

DeepTarget tool uncovers primary and secondary drug targets across cancer types

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

18 Nov 2025

Apriori Bio and A*STAR collaborate to develop next-generation saRNA influenza vaccines

Apriori Bio, a Flagship Pioneering company focused on developing prospective, variant-resilient vaccines, and the Agency for Science, Technology and Research Infectious Diseases Labs (A*STAR IDL) announced a strategic research partnership to co-develop and evaluate next generation self-amplifying RNA (saRNA) vaccines targeting seasonal and pandemic influenza.

18 Nov 2025

DeepTarget: A new tool for drug repurposing in oncology

14 Nov 2025

New technique revolutionizes the design of drugs that target ion channels

An international team involving the Institute of Chemical Research, a joint centre of the University of Seville and the Spanish National Research Council, has developed a new technique that will accelerate the design of drugs that target ion channels, a type of cell membrane protein involved in numerous diseases, ranging from psychiatric disorders to various types of cancer.

14 Nov 2025

Drug Discovery & Pharmaceuticals

Two compounds sourced from cannabis show promising anti-cancer effects

SN101 iPSC-derived therapy relieves chronic pain and preserves joints

Novel nanomedicine mPEG@ELA-11 shows potential in treating atherosclerosis

Exclusive licensing agreement accelerates PHD inhibitor development for anemia in CKD patients

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Collaborative project seeks safer therapies for ischemia and reperfusion injury

Older chemical libraries yield new leads for next-generation COVID-19 antivirals

Ripple & Bausch’s licensing agreement: What it means in ocular delivery

Atelerix and Labskin partner to enable long-distance transport of advanced in vitro skin models

Generative AI aids discovery of ISM3830's novel scaffold

Designing better RNA delivery polymers with computational tools

Eli Lilly’s Adverum move: The future of ocular gene therapy at the 4th Ophthalmic Drug Delivery Summit

Freezing cells for success: DMSO-free redefining the future of cryopreservation

Research explores new solvent strategies to extend shelf life of injectable therapeutics

Promising long-term vaccine for Crimean-Congo hemorrhagic fever developed

New light-activated method revolutionizes creation of drug building blocks

DeepTarget tool uncovers primary and secondary drug targets across cancer types

Apriori Bio and A*STAR collaborate to develop next-generation saRNA influenza vaccines

DeepTarget: A new tool for drug repurposing in oncology

New technique revolutionizes the design of drugs that target ion channels

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest Life Science News